Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about Ascelia Pharma:
TOP STORIES
Ascelia Pharma provides update on the Orviglance NDA
2026-07-03
Ascelia Pharma AB (publ) (ticker: ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced that it has received a Complete Response [& …
TOP STORIES
Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing
2026-06-30
Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application […]
TOP STORIES
Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review
2025-11-15 10:15:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) [… …
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Quarterly Report Q1 2026: Orviglance® Approaching Transformative MilestonesAnnual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for ReviewQuarterly Report Q3 2025: Orviglance NDA Submitted to the FDAHalf-Year Report 2025: Orviglance NDA Submission Approaching